BioCentury | Sep 1, 2020
Product Development

Aug. 31 Quick Takes: Mylan, Biocon launch cheaper insulin in U.S.; plus: AZ, bluebird, Lipocine, Amgen, AbbVie-Morphic, Polyphor-Fosun and Milestone

...to license antifibrotic integrins to block TGF β activation (see “AbbVie, Morphic Partner”).Polyphor, Fosun to develop balixafortide...
...in ChinaPolyphor AG (SIX:POLN) and Shanghai Fosun Pharmaceutical (Group) Co. Ltd. will develop and commercialize balixafortide...
BioCentury | Jul 31, 2020
Finance

Polyphor gains financial cushion ahead of Phase III readout of lone clinical program

...year, when it expects the first readout of overall response rate data for lead program balixafortide...
...According to CEO Gokhan Batur, the data could turn out one of several ways. If balixafortide...
...receptor 4 HER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor 2 Stephen Hansen, Associate Editor balixafortide (POL6326) Polyphor...
BioCentury | Mar 30, 2018
Clinical News

Polyphor reports Phase Ib data for breast cancer candidate

...treated HER2-negative, CXC chemokine receptor 4 (CXCR4; NPY3R)-positive metastatic breast cancer showing that IV balixafortide (POL6326...
...each 21-day cycle. The candidate is a CXCR4 inhibitor. Polyphor Ltd., Allschwil, Switzerland Product: Balixafortide (POL6326...
...progression-free survival (PFS) and overall survival (OS) Status: Phase Ib data Milestone: NA Jaime De Leon balixafortide (POL6326) Polyphor...
BioCentury | Dec 4, 2014
Strategy

Merck Encycles through Canada

...have fewer intramolecular hydrogen-bonding motifs. The most advanced macrocycle in development is Polyphor Ltd. 's POL6326...
BioCentury | Sep 17, 2012
Product Development

Excited about cycling

...Polyphor are the only companies with macrocyclic compounds in the clinic. Polyphor's lead compound is POL6326...
...2006 ND Polyphor Ltd. MacroFinder macrocycle platform and PEMfinder (protein epitope mimetics) cyclic peptide platform POL6326...
BioCentury | Sep 4, 2008
Targets & Mechanisms

CXCR4 for CNS Infections

...Phase I/II Chemokine Therapeutics CTCE-0214 SDF-1 analogA Neutropenia; stem cell mobilization Phase I Polyphor Ltd. POL6326...
BioCentury | Jul 14, 2008
Clinical News

POL6326: Phase I data

...In a U.K. Phase I trial in 74 healthy volunteers, POL6326 was well tolerated. The compound...
...tolerated. The compound also mobilized HSCs into the bloodstream. Polyphor Ltd. , Allschwil, Switzerland Product: POL6326...
Items per page:
1 - 7 of 7